Forza Wealth Management LLC Has $1.47 Million Stake in Johnson & Johnson $JNJ

Forza Wealth Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,604 shares of the company’s stock after buying an additional 81 shares during the period. Forza Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,467,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. HBW Advisory Services LLC increased its holdings in shares of Johnson & Johnson by 13.3% in the first quarter. HBW Advisory Services LLC now owns 7,401 shares of the company’s stock valued at $1,227,000 after purchasing an additional 867 shares during the last quarter. RFG Advisory LLC increased its holdings in shares of Johnson & Johnson by 9.0% in the first quarter. RFG Advisory LLC now owns 18,278 shares of the company’s stock valued at $3,031,000 after purchasing an additional 1,515 shares during the last quarter. Whipplewood Advisors LLC increased its holdings in shares of Johnson & Johnson by 5.3% in the first quarter. Whipplewood Advisors LLC now owns 1,636 shares of the company’s stock valued at $295,000 after purchasing an additional 82 shares during the last quarter. Finally, Apella Capital LLC increased its holdings in shares of Johnson & Johnson by 13.6% in the first quarter. Apella Capital LLC now owns 27,649 shares of the company’s stock valued at $4,174,000 after purchasing an additional 3,314 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on JNJ. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Finally, Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $181.40.

Johnson & Johnson Trading Up 0.3%

JNJ opened at $185.99 on Thursday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $186.56. The company has a 50-day simple moving average of $175.45 and a 200 day simple moving average of $162.51. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $447.92 billion, a price-to-earnings ratio of 19.89, a P/E/G ratio of 2.36 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the prior year, the business posted $2.82 earnings per share. Johnson & Johnson’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.